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updates on causes, mechanisms and management1350-7540  2013 Wolters Kluwera,b a cManuel Diezi , Thierry Buclin , and Thierry KuntzerPurpose of review
This review discusses publications highlighting current research on toxic, chemotherapy-induced peripheral
neuropathies (CIPNs), and drug-induced peripheral neuropathies (DIPNs).
Recent findings
The emphasis in clinical studies is on the early detection and grading of peripheral neuropathies, whereas
recent studies in animal models have given insights into molecular mechanisms, with the discovery of novel
neuronal, axonal, and Schwann cell targets. Some substances trigger inflammatory changes in the
peripheral nerves. Pharmacogenetic techniques are underway to identify genes that may help to predict
individuals at higher risk of developing DIPNs. Several papers have been published on chemoprotectants;
however, to date, this approach has not been shown effective in clinical trials.
Summary
Both length and nonlength-dependent neuropathies are encountered, including small-fiber involvement.
The introduction of new diagnostic techniques, such as excitability studies, skin laser Doppler flowmetry,
and pharmacogenetics, holds promise for early detection and to elucidate underlying mechanisms. New
approaches to improve functions and quality of life in CIPN patients are discussed. Apart from developing
less neurotoxic anticancer therapies, there is still hope to identify chemoprotective agents (erythropoietin
and substances involved in the endocannabinoid system are promising) able to prevent or correct painful
CIPNs.
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Drug-induced peripheral neuropathies (DIPNs) are
uncommon, but with the number of new drugs
increasing, unusual side effects may not become
apparent until after widespread usage. Chemother-
apy-induced peripheral neuropathies (CIPNs) are
major and dose-limiting side effects of many anti-
cancer treatments, and their characteristics are
often related to both the choice of anticancer
drugs and the cumulative doses [1]. Toxic, DIPNs,
and CIPNs may appear as length or nonlength-
dependent neuropathies, with or without small-
fiber involvement, and discussions about grading
the severity and early detection of neuropathies
are still open. Recent publications have revealed
new insights into the description and under-
standing of the pathophysiology and individual
susceptibility factors, paving the way for the
development of new prophylactic and therapeutic
measures.Health | Lippincott Williams & WilkCLINICAL MANIFESTATIONS AND
ASSESSMENT
As the most frequently encountered neuropathic
mechanisms target neurons or their axons (see
Table 1 and Fig. 1), toxic, DIPNs, and CIPNs are
mainly most often characterized by the develop-
ment of a subacute or chronic, length-dependent,
distal, symmetrical polyneuropathy with a predo-
minant sensory involvement, with or without
associated dysautonomia. This corresponds to theins www.co-neurology.com
KEY POINTS
 For toxic neuropathies, no real therapeutic
breakthroughs but some interesting new insights in
pathophysiology are available.
 Adequate animal models and pharmacogenetic data
are important for future advances in toxic neuropathies.
 Functional assessment for early detection is necessary
when using potentially neurotoxic therapy.
Nerve, neuro-muscular junction and motor neuron diseasesso-called ‘dying back axonal degeneration’ affecting
distal segments of the peripheral nerves. Interest-
ingly, most chemotherapeutic drugs poorly pene-
trate through the blood–brain barrier, but readily
pass through the blood–nerve barrier, probably
explaining the clinical observation of toxic damage
preferentially affecting the sensory neurons of
the dorsal root ganglia (DRG). These induced
sensory neuronopathies are now more easily recog-
nized by newly proposed diagnostic strategies
[48]. Chronic alcoholic neuropathy, vitamin-related
neuropathies, and CIPNs (platin compounds, vinka
alkaloids, taxanes, bortezomib, and thalidomide)
are classical examples of substance-induced neuro-
pathies, and have been recently extensively
reviewed [33
&&
,49,50
&&
,51,52
&
]. CIPN is one of the
main reasons for patients to prematurely terminate
antineoplastic treatment. This is now well recog-
nized [53–55], but as the number of long-term
cancer survivors increases, new methods of rehabil-
itation are discussed to improve the patients’ func-
tions and quality of life [50
&&
,56]. Other recently
recognized DIPNs include those from long-term
triazole antifungal therapies [57] – ixabepilone for
metastatic breast cancer [58], bendamustine for lym-
phomas [59], and stavudine in children receiving
antiretroviral treatment [60]. Less toxic and poten-
tially superior alternatives are now reported for the
management of nonsmall cell lung cancer [61] and
for the front-line treatment of advanced gastric or
gastroesophageal adenocarcinoma [62].
More rarely, a nonlength-dependent or multi-
focal neuropathy may be encountered, either
resembling chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP) or Lewis Sumner
syndrome in DIPN associated with underlying
inflammatory or dysimmune mechanisms [11,63].
A nonlength-dependent small-fiber neuropathy
may also be observed [64], such as in nitrofurantoin
toxicity [65].
Assessment and grading of peripheral neuro-
pathies remain subject to discussions [66], as most
of the frequently used scales and grading systems482 www.co-neurology.comrely on subjective evaluation either by the patient
or the examiner. This is well illustrated in CIPN,
where use of one of the classical grading systems,
the National Cancer Institute Common Toxicity
Criteria (NCI-CTC), tends to overestimate motor
neuropathies compared to a composite scale
designed to grade impairment in neuropathy
patients [Total Neuropathy Score (TNS)] [67],
despite both grading systems having good inter
and intra-observer reproducibility [52
&
]. The newly
developed Chemotherapy-Induced Neurotoxicity
Questionnaire (CINQ) and the Functional Assess-
ment of Cancer Therapy/Gynaecologic Oncology
Group/Neurotoxicity (FACT/GOG-Ntx) question-
naire acknowledge a considerable negative impact
of neuropathy symptoms on daily activities in
cancer patients treated with chemotherapy [68].
Quantification or early detection is a persistent
matter of debate, but new noninvasive tools for
diagnosis are emerging, such as nerve excitability
studies utilizing threshold tracking techniques [69],
or laser Doppler flowmetry quantifying the small-
fiber impairment by the reduced axon-reflex flare
areas [70].WHAT HAVE WE LEARNED FROM ANIMAL
MODELS?
Several animal models have been generated over the
past years with the aim of understanding the patho-
physiology of CIPN and DIPN, and importantly to
design specific chemoprotective agents and anal-
gesic drugs for neuropathic pain [71]. A mouse
model study has confirmed that the presence of
neuropathy before treatment with an antitumoral
agent such as bortezomib results in a more marked
involvement of peripheral nerves [72], which may
be one of the factors rendering some individuals
more vulnerable to neurotoxic medications.
Evidence from animal models of CIPN indicates
that neuropathy may occur via a common mechan-
ism having a toxic effect on the mitochondria in
primary afferent sensory neurons. This has been
shown in a model of bortezomib-induced painful
peripheral neuropathy in the rat, where mitotox-
icity is the core pathological finding (see ‘Update on
themolecular mechanisms’ section below); interest-
ingly, prophylactic treatment with acetyl-L-carni-
tine completely blocked bortezomib’s effects on
mitochondria and the development of pain [22].
Mitochondrial dysfunction resulting in the pro-
duction of neuropathic pain is also suggested from
another study on paclitaxel and oxaliplatin-induced
neuropathy in rats [14]. A cisplatin-induced hyper-
algesia model in mice was used to study the anti-
hyperalgesic effects of anandamide and URB597, anVolume 26  Number 5  October 2013
Table 1. Neurotoxic drugs, putative mechanisms, and potential management
Neurotoxicity mechanisms (numbers refer to Fig. 1) Drugs
Reported potential molecules for
management
DRG cytotoxic
inflammatory
changes (1)
Thalidomide [2]
Bortezomib [3,4]
Cisplatin [5] N-acetylcysteine [6], melatonin [7],
amifostine, glutathione, vitamin E,
pregabalin, and gabapentin [8]
NRTIs [9] Etanercept [10]
Tacrolimus [11]
Mitotoxicity and oxidative
stress (2)
Paclitaxel [12–14] Glutamine [15], vitamin E [16,17],
AV411 (ibudilast) [18], EPO, [19],
olesoxime and acetyl-N-carnitine [20],
minocycline [21&], melatonin [7]
Bortezomib [22] Acetyl-L-carnitine [22]
Platinum
compounds [23&]
Silibinin [23&], olesoxime, and
acetyl-L-carnitine [24]
NRTIs [25]
Anti-VEGF
compounds [26,27&]
Microtubular function
disruption (3)
Vincaalcaloids NSAIDs [28], propentofylline [29]
Paclitaxel [12]
Epothilones [30]
Voltage-gated ion channel
dysfunction (4)
Sodium channels Oxaliplatin [31] Lidocaine [32], pregabalin and
gabapentin [8], glutathione, glutamine
and oxcarabazepine [33&&], calcium
or magnesium salts [34]
Potassium channels Cisplatin [35] Retigabine [36]
Oxaliplatin [37,38]
Calcium channels Cisplatin [35] Nimodipine and calmodulin inhibitors
[39], calcium or magnesium salts [8]
Paclitaxel [40]
Dysfunction of TRP family
of ion channels (5)
Ankyrin 1 (TRPA1) Paclitaxel [6] HC0300031 [41]a
Oxaliplatin [42]
Vanilloid 1 (TRPV1) Cisplatin [43] Capsazepine and SB366791 [41]a
Vanilloid 4 (TRPV4) Paclitaxel [6] RN1734 [41]a
DRG neuronal apoptosis
(6)
Cisplatin [44]
Bortezomib [4]
Demyelination (7) Decreased myelin
sheath methylation
Nitrous oxide [45] Vitamin B12 [45]
Immune-based
demyelination
Etanercept, infliximab,
adalimumab [46]
IVIG [47]
Oxaliplatin [47] IVIG [47]
Reduction of VEGF
neuroprotective effect (8)
? Bevacizumab [27&]
Sorafenib [27&]
Sunitinib [27&]
N.B.: most of the substances listed here have been evaluated in preclinical settings. DRG, dorsal root ganglion; EPO, erythropoietin; IVIG, intravenous
immunoglobulin; NRTIs, nucleoside analog reverse-transcriptase inhibitors; TRP, transient receptor potential; VEGF, vascular endothelial growth factor.
aHC0300031, RN1734, capsazepine, and SB366791 are antagonists of TRPA1, TRPV1, and TRPV4, respectively.
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FIGURE 1. Neuronal targets of drug-induced peripheral neuropathy (numbers refer to Table 1).
Nerve, neuro-muscular junction and motor neuron diseasesinhibitor of anandamide hydrolysis implicated in
the endocannabinoid system. Although the mech-
anisms by which anandamide reduces neurotoxicity
and prevents development of neuropathy remain to
be resolved, this study underscores the potential
utility of stimulating the endocannabinoid system
for the management of neuropathic pain produced
by chemotherapy [73].
Another recent finding is the identification
of a molecular self-destruction cascade in axonal
degeneration. A model of toxic neuropathy in
Drosophila has been designed and shares somemole-
cular execution mechanisms with vertebrates [74].
This new model could be used to identify evolutio-
narily conserved genes involved in axonal degenera-
tion, which could represent potential targets for
therapy.
A direct neurotrophic role for vascular endo-
thelial growth factor (VEGF) has recently been
demonstrated. Systemic VEGF inhibition (using
bevacizumab, a neutralizing VEGF antibody, and
sorafenib and sunitinib, VEGF receptor inhibitors),
in combination with chemotherapy, improves the
outcome of patients with metastatic cancer. Peri-
pheral sensory neuropathies occurring in patients
receiving both drugs were traditionally attributed to
the chemotherapy drug(s) alone. Using transgenic
mice with altered neuronal VEGF receptor expres-
sion, systemic inhibition of VEGF receptors was484 www.co-neurology.comshown to interfere with the endogenous neuropro-
tective action of VEGF on sensory neurons, thus
providing unprecedented evidence that VEGF recep-
tor inhibitors may themselves trigger a painful
neuropathy and aggravate paclitaxel-induced neuro-
pathies [27
&
].
The role of neurographic in-vivo molecular
imaging has also been addressed. Imaging changes
were observed in a model of oxaliplatin-induced
neuropathy, implying impaired retrograde neural
transport, thought to be important in the patho-
physiology of this neuropathy [75].UPDATE ON THE MOLECULAR
MECHANISMS
Molecular causes of DIPN have been addressed
in several studies. Specific neuronal and non-
neuronal dysfunctions leading to disruption of
common pathways have been postulated and are
summarized in Table 1 and Fig. 1; these include
DRG cytotoxic inflammatory changes, mitotoxic-
ity and enhanced oxidative stress, microtubular
function dysruption, voltage-gated ion channel
(VGIC) dysfunction, functional impairment of
ion channels of the transient receptor potential
(TRP) family, induction of neuronal apoptosis in
DRG, demyelination, and reduction of VEGF neuro-
protective action.Volume 26  Number 5  October 2013
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Endoneurial macrophage infiltration and sub-
sequent secretion of pro-inflammatory cytokines
[tumor necrosis factor alpha (TNFa), interleukin 1
beta (IL-1b), IL-6, and IL-8, and chemokines C-C
motif ligand 2 (CCL2), CXC family], growth factors,
and inflammatory mediators such as bradykinin,
prostaglandins, serotonin, and nitric oxide have
been correlated with acute and chronic neuropathic
pain in human CIPN or in patients receiving highly
active antiretroviral therapy (HAART) agents [9,21
&
].
In animal models, overexpression of matrix metal-
loproteinases mediating myelin turnover and
phenotypic remodeling of glial and neuronal cells,
as well as secondary activation of inflammatory
cascades, have been recently reviewed [21
&
].
In some DIPNs, medication-induced immune
perturbation presumably triggers a dysimmune
attack directed at unidentified peripheral nerve
myelin epitopes; true peripheral nerve toxicity (i.e.
dependent on accumulative dose or serum level)
plays no identified role. TNFa blocking molecules
and other immunomodulatory, immunosuppres-
sive, or antineoplastic agents, widely used to treat
several forms of inflammatory diseases, have
been associatedwith dysimmune conditions, includ-
ing various forms of demyelinating neuropathies
[11,46,63,76].Mitochondrial toxicity and oxidative stress
The recently discoveredmechanisms of mitotoxicity
include a link between abnormal opening of the
mitochondrial permeability transition pore (mPTP),
amitochondrial calcium leak, anda secondaryorgan-
elle swelling leading to neuronal hyperexcitability
[21
&
]; disruption of themitochondrial electron trans-
port chain (mETC) in inflammatory-induced neuro-
pathic pain, with the demonstration that inhibition
of the mETC complexes can counteract dideoxycyti-
dine and TNFa-induced neuropathic pain [9]; and
enhanced oxidative stress, with impairment in
the mediated respiration complexes following the
administration of paclitaxel, docetaxel vincristine,
oxaliplatin, and bortezomib, causing secondary
production of pro-inflammatory cytokines [13,14,
22,24]. Oxidative stress may be particularly import-
ant, based on the significant correlation between the
glutathione-S-transferase P1 (GSTP1) genotype and
thedevelopmentofmore severeor earlier-onsetCIPN
following docetaxel administration [77].Ion channels
Dysfunction of the peripheral nerve VGICs has been
advocated as a potential cause of DIPN.1350-7540  2013 Wolters Kluwer Health | Lippincott Williams & WilkSodium
Oxaliplatin-induced neuropathy has been suggested
from human ex-vivo and animal models to be
hyperexcitability secondary to an altered state of
the voltage-gated sodium channel, in particular
the channel Nav1.6 [31]. These results have led to
the experimental use of sodium channel blockers in
animal disease models [78,79
&
].Potassium
Other authors, using a cellularmodel of oxaliplatin-
induced neuropathy, have noted that dysfunc-
tion of the voltage-gated potassium channel may
also be associated with nerve hyperexcitability
[38,80].Calcium
Alterations in voltage-gated calcium channel cur-
rents in the ratDRG interferingwith calciumhomeo-
stasishavebeenassociatedwithCIPN, especiallywith
platinum compounds and taxanes [40,81].Transient receptor potential ion channels
TRP channels are a group of ion channels widely
expressed in neuronal (e.g. sensory DRG and trige-
minal ganglia neurons) and in non-neuronal cells,
located mainly on the plasma membrane. They
are rather nonselectively permeable to sodium,
calcium, and magnesium, and mainly involved in
the transduction of a variety of painful or thermal
stimuli [82
&
,83]. Several members of this family of
receptors have been linked to DIPN, mainly secon-
dary to oxaliplatin and paclitaxel, through a mech-
anism of oxidative stress generation; these include
TRP vanilloid 1 (TRPV1, capsaicin receptor), 2, 3, 4,
and 8 (menthol receptor), and ankyrin 1 (TRPA1)
[6,41,42].Microtubules
Perturbation of axonal transport secondary to inhi-
bition of microtubule dynamics or excessive tubulin
polymerization has been well described in toxic and
CIPN, and has been recently extensively reviewed
[1,33
&&
].Apoptosis
A painful sensory neuropathy has been associated
with VEGF-neutralizing antibodies (bevacizumab)
or VEGF receptor inhibitors (sorafenib, sunitinib;
see ‘What have we learned from animal models?’
section above), which are usually administered in
combined chemotherapy regimens. This involves
disruption of the neuroprotective effect of VEGF,ins www.co-neurology.com 485
Nerve, neuro-muscular junction and motor neuron diseasesleading to neuronal stress and apoptosis through a
mechanism involving VEGF receptor-2-mediated
expression of the antiapoptotic protein Bcl2
[27
&
,33
&&
,50
&&
].
In another setting, mefloquine, an efficient
therapeutic option for drug-resistant Plasmodium
falciparum malaria, is associated with a clinically
well described, but pathophysiologically poorly
understood, neurotoxicity [84]. A recent study
linked mefloquine to a down-regulation of a non-
receptor tyrosine kinase, Pyk2, involved in ion
channel regulation through activation of the MAP
kinase signaling pathway, ultimately leading to
oxidative injury and apoptosis [85].PHARMACOGENETIC SUSCEPTIBILITY
Pharmacogenetic variations in absorption, distri-
bution, metabolism, elimination, and DNA repair
mechanisms have been postulated to explain differ-
ences in the observed neurotoxicity of various mole-
cules. For instance, polymorphisms of the gene
encoding ABCB1/P-glycoprotein, one of the trans-
porters involved in the elimination of numerous
xenobiotic substances, have been suggested to parti-
ally explain the variability of taxane-induced
DIPN [86,87]. Similarly, genetic variants of proteins
involved in the metabolism of xenobiotics, for
example, cytochrome 3A5, have been linked to
increased risk of DIPN in children receiving vincris-
tine [88].
Likewise, increased susceptibility to peripheral
neurotoxicity after exposure to offending agents has
been associated with polymorphisms in genes
involved in the following pathways: chemother-
apy-induced DNA adducts repair [89], immune
function (CTLA4, CTSS), reflexive coupling within
Schwann cells (GJE1), drug binding (PSMB1), and
neuron function (TCF4, DYNC1I1) [90], apoptosis
[4], mitochondrial dysfunction, inflammation [2],
and oxidative stress scavengers such as glutathione
S-transferase 1 (GST1) [91].TREATMENT
There are no real breakthroughs for the treatment of
CIPN. Data from an experimental animal model
completed by a randomized controlled trial in
patients with nonsmall cell lung cancer treated with
cisplatin showed that activators of retinoid recep-
tors stimulate nerve growth factor andmay improve
nerve conduction [92]. Prophylactic dosing with
two drugs, acetyl-L-carnitine and olesoxime, known
to protect mitochondria, has been shown to signifi-
cantly reduce the development of pain hyper-
sensitivity to bortezomib in animal models [92].486 www.co-neurology.comIn another model of oxaliplatin-induced painful
neuropathy, improvement in oxidative alterations
and pain relief was established with natural anti-
oxidant compounds such as a-tocopherol and
silibinin [23
&
].
The 2011 Cochrane review concluded that the
data in human patients are insufficient to conclude
that any of the purported chemoprotective agents
(acetylcysteine, amifostine, calcium and magnes-
ium, diethyldithiocarbamate, glutathione, Org
2766, oxycarbazepine, or vitamin E) prevent or limit
the neurotoxicity of platinum compounds [93]. A
randomized phase III clinical trial has recently con-
firmed that vitamin E did not reduce the incidence
of sensory neuropathy [17]. During a validation
study of the French FACT/GOG-Ntx questionnaire
for assessing CIPN, the study raised the possibility
that erythropoietin might play a neuroprotective
role when administered with paclitaxel [94
&
]. The
successful treatment with vitamin B12 injections in
cobalamin deficiency and subacute combined
degeneration after nitrous oxide anesthesia is again
underscored [45]. Several substances have been
studied in the past for treating inflammatory causes
of DIPN, and recently melatonin [7] and kinin
receptor antagonists [95] have been tested in pre-
clinical models, showing some positive effects.
The outcome of DIPN as a neurological compli-
cation associated with immune modulators (TNFa
blockers and alike) has been reported to be favorable
in most cases. Although there are no clear-cut
recommendations so far on the management of
these secondary DIPNs, it is probably advisable to
stop the treatment when complications occur, or
to treat with steroids or intravenous immuno-
globulins.CONCLUSION
Promising progresses have been made over the past
couple of years in understanding both the patho-
physiological mechanisms and potential thera-
peutic options of DIPN. Such advances have
required the use of adequate animal models and
sufficiently powered clinical studies. Future steps
should include pursuing these efforts, trying to link
together all the information mentioned above
regarding these pathophysiological mechanisms,
as well as combining inwell designed studies reliable
efficacy and toxicity outcome measures, pharmaco-
genetic data, offending drug dose adaptation, and
mechanism-based treatment.Acknowledgements
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